J&J "Dear Healthcare Provider" Letter On Risperdal Leads To $257.7 Million Jury Award

A jury finds that J&J misrepresented the safety profile of Risperdal in a verdict for the state of Louisiana; each letter and sales rep call was counted as a separate violation.